Amicidin-β/EF

About Macro Biologics

Macro Biologics is a private, preclinical-stage biotech leveraging a proprietary platform to create synthetic biological polymers with applications in therapeutics, medical devices, and environmentally safe biomaterials. The company's lead programs are the Amicidins, a novel class of products designed to prevent life-threatening infections in surgical and traumatic wounds, with significant backing from U.S. Department of Defense and global antibiotic resistance initiatives like CARB-X. While currently pre-revenue, the company has secured non-dilutive grant funding to advance its pipeline, targeting a massive unmet need in surgical site infections and antimicrobial resistance.

Therapeutic Areas